Trial NCT03894540

View at ClinicalTrials.gov 
Org. Study IDs: D-US-60090-001
Secondary IDs: 2018-003681-13

Last trial update was posted on 2022-09-13

MeSH Interventions

Paclitaxel Pembrolizumab

MeSH Conditions

Neoplasms

Other Conditions

Solid Tumor

Stopping Reasons

Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090

Limitations And Caveats

The study was terminated by the sponsor following an internal portfolio review during the dose escalation phase (Part A). The early termination was not due to any safety or tolerability issues with IPN60090.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID